SCHEMBL23833576

SCHEMBL23833576

Cc1cc(NN)ncc1S(=O)(=O)N1CCCC1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.55
▸ GAA P10253 1/20 0.55
▸ SMN1; SMN2 Q16637 4/20 0.48
▸ L3MBTL1 Q9Y468 2/20 0.48
▸ POLB P06746 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ CNR1 P21554 1/20 0.46
▸ ALDH1A1 P00352 4/20 0.46
▸ TSHR P16473 2/20 0.43
▸ LMNA P02545 1/20 0.43
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ TP53 P04637 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ THRB P10828 1/20 0.42
▸ PKM P14618 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16455682 0.79 POLB (0.56) KDM4EGAASMN1; SMN2L3MBTL1POLB
SCHEMBL30096914 0.77 PDIA6 (0.39) KDM4EGAATDP1MEN1KMT2A
SCHEMBL30094638 0.77 L3MBTL1 (0.42) KDM4EGAAL3MBTL1TDP1MEN1
SCHEMBL23833549 0.77 PDIA6 (0.39) KDM4EGAATDP1MEN1KMT2A
SCHEMBL23833547 0.77 L3MBTL1 (0.42) KDM4EGAAL3MBTL1TDP1MEN1
SCHEMBL17808302 0.75 SMN1; SMN2 (0.56) KDM4EGAASMN1; SMN2L3MBTL1POLB
SCHEMBL25518454 0.74 CDK1 (0.37) KDM4EGAAL3MBTL1TDP1MEN1
SCHEMBL23833536 0.71 HTT (0.43) KDM4EGAASMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL25518530 0.71 KDM4E (0.33) KDM4EGAATDP1MEN1KMT2A
SCHEMBL2767267 0.68 SMN1; SMN2 (0.61) KDM4EGAASMN1; SMN2L3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159489-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2023-05-25 — — US disclosed
EP-4121426-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE Akebia Therapeutics Inc. (US) 2023-01-25 — — EP disclosed
CN-115515948-A PHD inhibitor compounds, compositions and uses 阿克比治疗有限公司 2022-12-23 — — CN disclosed
WO-2021188938-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2021-09-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159489-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE HIF1AN, EGLN3, PHF20 KDM4E 69/4885GAA 3851/4885SMN1; SMN2 4853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback